Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for helicobacter pylori infection in type 2 diabetes mellitus patients

Southern Medical Journal

Volumn 102, Issue 11, 2009, Pages 1116-1120

  Gokturk, Huseyin Savas ^a   Demir, Mehmet ^b   Ozturk, Nevin Akcaer ^b   Arslan, Hande ^b   Serin, Ender ^b   Yilmaz, Ugur ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b NONE

Author keywords

Clarithromycin resistance; Diabetes mellitus; Eradication therapy; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL DNA; CLARITHROMYCIN; INSULIN; MACROLIDE; ORAL ANTIDIABETIC AGENT; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RNA 23S;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POINT MUTATION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH BIOPSY; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 73849132932     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181bca538     Document Type: Article

References (34)

1. Louw JA, Marks IN. Peptic ulcer disease. Curr Opin Gastroenterol 2004;20:533-537.
2. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384.
3. Tankovic J, Lamarque D, Lascols C, et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole- amoxicillinclarithromycin therapy. Aliment Pharmacol Ther 2001;15:707-713. (Pubitemid 32385877)
4. Dzierzanowska-Fangrat K, Rozynek E, Celińska-Cedro D, et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Int J Antimicrob Agents 2005;26:230-234.
5. Gulcelik NE, Kaya E, Demirbas B, et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005;28:214-217.
6. Oldensburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 1996;41: 458-461.
7. Candelli M, Rigante D, Marietti G, et al. Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics 2003;111:800-803.
8. Gasbarrini A, Ojetti V, Pitocco D, et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11:713-716.
9. Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260-263.
10. Bégué RE, Gómez R, Compton T, et al. Effect of Helicobacter pylori eradication in the glycemia of children with type 1 diabetes: a preliminary study. South Med J 2002;95:842-845.
11. Sargýn M, Uygur-Bayramicli O, Sargýn H, et al. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003;9:1126-1128.
12. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186.
13. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of H pylori infection-the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167-180.
14. Tankovic J, Lamarque D, Lascols C, et al. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole- amoxicillin-clarithromycin therapy. Pathol Biol (Paris) 2001;49: 528-533. (Pubitemid 32917004)
15. Calvet X, Garcia N, López T, et al. A metaanalysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-609.
16. Kadayifci A, Buyukhatipoǧlu H, Koruk M, et al. Turkiye'de H pylori eradikasyonunda PPI, amoksisilin ve klaritromisin tedavisinin etkinliǧi: meta-analiz. Turk J Gastroenterol 2004;15(suppl 1):5.
17. Aydin A, Onder GF, Akarca US, et al. Klaritromisine duyarli ve direncli olgularda bir ve iki haftalk pantoprazolamoksisilin- klaritromisin tedavilerinin Helicobacter pylori eradikasyonundaki etkinliǧi. Turk J Gastroenterol 2004;15(suppl 1):151.
18. Sezgin O, Aslan G, Altintaçs E, et al. Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey Turk J Gastroenterol 2008;19:163-167.
19. Quatrini M, Boarino V, Ghidoni A, et al. Helicobacter pylori prevalence in patients with diabetes and its relationship to dyspeptic symptoms. J Clin Gastroenterol 2001;32:215-217.
20. Malecki M, Bień AI, Galicka-Latalla D, et al. The prevalence of Helicobacter pylori infection and types of gastritis in diabetic patients. The Krakow study. Exp Clin Endocrinol Diabetes 1996;104:365-369.
21. Xia HH, Talley NJ, Kam EP, et al. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001;96:1039-1046.
22. Gasbarrini A, Ojetti V, Pitocco D, et al. Helicobacter pylori infection in patients affected by insulin-dependent diabetes mellitus. Eur J Gastroenterol Hepatol 1998;10:469-472.
23. Woodward M, Morrison C, Mccoll K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 2000; 53:175-181. (Pubitemid 30151223)
24. Rosenstock SJ, Jørgensen T, Andersen LP, et al. Association of Helicobacter pylori infection with lifestyle, chronic diseases, body-indices and age at menarche in Danish adults. Scand J Public Health 2000;28:32-40.
25. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991;20:477-490.
26. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987;82:29-35. (Pubitemid 17231680)
27. Groop LC, De Fronzo RA, Luizi L, et al. Hyperglycemia and absorption of sulphanylurea drugs. Lancet 1989;2:129-130.
28. Tooke JE. Microvascular haemodynamics in diabetes mellitus. Clin Sci (Lond) 1986;70:119-125.
29. Kong MF, Macdonald IA, Tattersall RB. Gastric emptying in diabetes. Diabet Med 1996;13:112-119.
30. McMahon BJ, Hennessy TW, Bensler JM, et al. The Relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-469.
31. Lõivukene K, Maaroos HI, Kolk H, et al. Prevalence of antibiotic resistance of H pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimen. Clin Microbial Infect 2002;8:598-603.
32. Ling TKW, Leung WK, Lee CC, et al. The antimicrobial susceptibility of H pylori in Hong Kong (1997-2001). Helicobacter 2002;7:327-329.
33. Candelli M, Rigante D, Marietti G, et al. Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. J Pediatr Gastroenterol Nutr 2004;38:422-425.
34. Ojetti V, Migneco A, Nista EC, et al. H pylori re-infection in type 1 diabetes: a 5 years follow-up. Dig Liver Dis 2007;39:286-287.